user avatar
Hope Rugo
@hoperugo
san francisco
Joined August 2012
Posts
  • user avatar
    So moved by DB04, although I knew the data & treated pts. Our goal as oncologists is to improve outcome - and when we succeed so dramatically in the largest subset of the most common cancer in women, it is truly a profound moment. In memory of my mother, for all my patients 🎉
  • user avatar
    Hot off the presses: FIRST ORAL SERD APPROVED FOR HR+/HER2- metastatic breast cancer! Elacestrant (Orserdu) approved for ESR1 mutated HR+ MBC after one line of ET. More options for our patients, one more step forward!
  • user avatar
    In the new year I honor wonderful young women we lost to MBC this year: a wonderful breast surgeon, a smart passionate pharmD, women just starting their lives. I am honored to have known them, their struggle & strength inspires me daily; I mourn what we have all lost
  • user avatar
    Very nice table of relative risks of breast cancer and associated germline mutations presented by susan Domchek at Miami BCC 2023 ⁦@gotoPER#MBCC2023@OncoAlert
  • user avatar
    The data speaks for itself. Destiny breast 04: TDXd beats TDM1 in HER2+MBC. Longest PFS ever in this setting. OS trending better. Low ILD. A new SOC. @myESMO @OncoAlert #ESMO2021 @JavierCortesMD
  • user avatar
    #esmo2025 remarkable study at a single center in India showed marked improvement in pCR with very low dose pembro vs none plus chemo in very high risk ES TNBC. Improving access worldwide to effective therapy!
  • user avatar
    Peter Schmid presents the OS data from KN522 #ESMO24 publl now in NEJM. >6 year FU: 9% EFS benefit, 5% ⬆️OS with pembro pre/post op for TNBC. Pts with PCR had 95% survival +/-pembro but 6% ⬆️OS in nonPCR + pembro. Safety same. Huge advance for TNBC. Need biomarkers! @OncoAlert
  • user avatar
    Important paper and remarkable results. Just had a dramatic response in a patient with HER2 low disease in brain and LM, started T-DXd after ASCO, have not seen anything like this before. Very impressive. @OncoAlert
    Does T-DXd work in HER2+ BC active brain metastases? Pretty clear answer in the below waterfall plot from #TUXEDO1 phase 2 trial, now published on @NatureMedicine. Impressive IC-ORR of 73%, mPFS 14 months, QoL maintained during Rx. Congrats to the authors! nature.com/articles/s4159…
  • user avatar
    A new treatment paradigm for metastatic HER2+ BC. Nice discussion of destiny breast 04 by Shanu Modi. ⁦@OncoAlert⁩ ⁦@myESMO#esmo2021
  • user avatar
    Feedback? Interested in your thoughts - first draft! Ongoing trials not included.... @OncoAlert @UCSFCancer
  • user avatar
    Nice summary by Harbeck Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer thebreastonline.com/article/S0960-… @OncoAlert
  • user avatar
    And now improved OS as well - to be presented at #ESMO22! A great team effort. ADCs are the chemo for the future - and that future is now. @UCSFCancer @OncoAlert
    Sacituzumab Govitecan Provides PFS Benefit Vs Chemotherapy in HR+/HER2– Breast Cancer @hoperugo @JCO_ASCO #bcsm ow.ly/t8gV50Kz7bz
  • user avatar
    Second interim analysis shows significant OS benefit! Trodelvy® Significantly Improves Overall Survival in Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients in the TROPiCS-02 Study. ⁦@OncoAlertgilead.com/news-and-press…
  • user avatar
    #SABCS21 here we come! Excited for the plenary in the morning and hoping I can stay on time for my discussion! Happy to see the friends who were able to attend. @OncoAlert